IP Library Granted Patent US 8,519,096
Granted Patent B2
US 8,519,096 · App. 13/239,329 · Granted Aug 27, 2013

Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,519,096
App. No.
13/239,329
Granted
Aug 27, 2013
Kind
B2
Abstract

The present invention provides novel citrullinated peptides, their use in methods for aiding, assisting, improving, or facilitating the diagnosis or prognosis of rheumatic diseases such as rheumatoid arthritis (RA), and methods for identifying novel citrullinated peptides that are immunoreactive with anti-citrullinated protein antibodies (ACPAs). The present invention also provides methods for detecting rheumatoid factor (RF) using novel RF detection reagents as a means to aid, assist, improve, or facilitate the diagnosis or prognosis of rheumatic diseases such as RA. Kits comprising at least one of the novel citrullinated peptides and/or RF detection reagents of the present invention are also provided.

Claims (28)

1. A synthetic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, and 67, wherein said peptide is immunologically reactive with an anti-citrullinated protein antibody.

2. The synthetic peptide of claim 1 , wherein said peptide further comprises a tag.

3. The synthetic peptide of claim 2 , wherein said tag is biotin.

4. A synthetic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, and 66 wherein said peptide is immunologically reactive with an anti-citrullinated protein antibody.

5. The synthetic peptide of claim 1 or 4 , wherein the C-terminus of said peptide is amidated.

6. The synthetic peptide of claim 1 or 4 , wherein said peptide further comprises a detectable moiety.

7. The synthetic peptide of claim 6 , wherein said detectable moiety is a fluorescent moiety.

8. A method for detecting an anti-citrullinated protein antibody in a biological sample, the method comprising the steps of:

(a) contacting the biological sample with a synthetic peptide of claim 1 or 4 under conditions suitable to transform said peptide into a complex comprising said peptide and anti-citrullinated protein antibody; and

(b) detecting the presence or level of said complex.

9. The method of claim 8 , wherein step (b) comprises the detection of a detectable moiety conjugated to said peptide.

10. The method of claim 9 , wherein said detectable moiety is a fluorescent moiety.

11. The method of claim 8 , wherein step (b) comprises the sub-steps of:

(i) contacting said complex with a detection reagent comprising a reporter group to transform said complex into a labeled complex; and

(ii) detecting the presence or level of said labeled complex.

12. The method of claim 11 , wherein said detection reagent is selected from the group consisting of an anti-IgA antibody, an anti-IgG antibody, an anti-IgM antibody, Protein L, Protein A, Protein G, and mixtures thereof.

13. The method of claim 11 , wherein said reporter group is selected from the group consisting of radioactive groups, fluorescent groups, luminescent groups, enzymes, biotin, and dyes.

14. The method of claim 11 , wherein detecting the presence or level of said labeled complex comprises detecting the presence or level of a signal generated from said reporter group.

15. The method of claim 11 , wherein said anti-citrullinated protein antibodies comprise IgG anti-citrullinated protein antibodies.

16. A kit comprising:

(a) at least one synthetic peptide of claim 1 or 4 ; and

(b) a detection reagent comprising a detectable moiety.

17. A kit comprising:

(a) at least one synthetic peptide of claim 1 or 4 ; and

(b) a detectable moiety linked to said at least one synthetic peptide.

18. The kit of claim 16 or 17 , wherein said detectable moiety is selected from the group consisting of radioactive groups, fluorescent groups, luminescent groups, enzymes, biotin, and dyes.

19. The kit of claim 16 , wherein said detection reagent is selected from the group consisting of an anti-IgA antibody, an anti-IgG antibody, an anti-IgM antibody, Protein L, Protein A, Protein G, and mixtures thereof.

20. The kit of claim 16 or 17 , wherein said at least one synthetic peptide is immobilized on a solid support.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CHANGE OF NAME Recorded Oct 17, 2019
From: PRECISION IBD, INC.
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 050886/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2019
From: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
To: PRECISION IBD, INC.
Reel/Frame 050166/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: PROMETHEUS LABORATORIES INC.
To: NESTEC S.A.
Reel/Frame 029504/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2012
From: LING, NICHOLAS CHI-KWAN; WANG, SHUI LONG; WANG, DUNRUI; SINGH, SHARAT
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 027867/0915 →